Pay in 4 interest-free payments of $5.45 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved single or dual agonists such as semaglutide and tirzepatide
Potential Exploratory Directions in Other Digestive System Diseases Beyond the aforementioned major areas, this drug has shown preliminary potential in other digestive system disorders
Some patients taking these medications have reported decreased interest in alcohol or smoking
After 2 hours, islets were subjected to either liraglutide (100 nM) (107, 108) or saline treatment for 12 hours (DART-Seq) (8, 85, 109) in order to assess changes in RNA expression or 24 hours (7, 85, 107) (IHC, active GLP-1 measurements) in order to assess changes in protein content, as previously validated (85)
GLP-1 weight loss medications are approved for specific patient populations based on BMI and health conditions
